I am a
Health plan professional
Formulary or population health decision maker
Healthcare provider, patient, or caregiver
This site is intended for payers or other professionals who make formulary and/or population health decisions within their organization.
I am a
Formulary or population health decision maker
Please make a selection belowⓧ
Login
Please enter a valid email addressInvalid User IDThank you for registering
Continue
ⓧ
Sign Up
Please correct errors belowPLEASE NOTE: Once registered, you will receive a follow-up email confirming access, typically within 2 business days.
By completing and submitting this form, you agree to sign up for communications from Neurocrine Biosciences. You are confirming you understand and agree to the Privacy Policy and Terms and Conditions.
Materials Available for Instant Download
Population Health Resources Overview
An overview of the population health resources available to help manage individuals with movement disorders, particularly TD
2020 APA Schizophrenia Practice Guideline: Managing Antipsychotic-Associated Movement Disorders for Individuals With Mental Illness
2020 APA Practice Guideline for the Treatment of Patients With Schizophrenia suggests baseline and follow-up assessments for antipsychotic-associated movement disorders, including recommendations for the management of TD
Additional Resources for Registered Users Include:
Patient Screener: Tardive Dyskinesia Means Having Movements You Can’t Control
A list of questions to help with the assessment of abnormal movements in patients taking antipsychotics for at least a few months.
Audience: Patients
A list of questions to help with the assessment of abnormal movements in patients taking antipsychotics for at least a few months.
Audience: Patients
The Importance of Treating Underlying TD in Patients with SMI
Details the impact of TD on health systems and patients with SMI, raising awareness of the need for consistent monitoring and proactive treatment within SMI populations.
Audience: HCPs, Case Managers, Formulary Decision-Makers
Details the impact of TD on health systems and patients with SMI, raising awareness of the need for consistent monitoring and proactive treatment within SMI populations.
Audience: HCPs, Case Managers, Formulary Decision-Makers